What is CONMED's cash & equivalents?

CONMED (CNMD) reported cash & equivalents of $35.03M in Q1 2026.

How has CONMED's cash & equivalents changed year-over-year?

CONMED's cash & equivalents decreased by 1.3% year-over-year, from $35.49M to $35.03M.

What is the long-term trend for CONMED's cash & equivalents?

Over 5 years (2020 to 2025), CONMED's cash & equivalents has grown at a 8.3% compound annual growth rate (CAGR), from $27.36M to $40.82M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

CONMED CNMD Cash & Equivalents

Cash & Equivalents at other companies

Johnson & JohnsonJNJ

$21.69B-43.6%

StrykerSYK

$2.88B+24.1%

Boston ScientificBSX

$850M+146%

VericelVCEL

$109.3M+37.1%

OSI SystemsOSIS

$345.24M+260%

Zimmer Biomet HoldingsZBH

$424.2M-69.4%

Other financials

Income statement

See full

Revenue$317.0M-1.3%

Gross profit$183.4M+3.2%

Operating income$25.4M+59.3%

Net income$13.8M+129%

EPS (diluted)$0.45+137%

Balance sheet

See full

Total debt$862.6M-3.6%

Total equity$1.0B+4.1%

Total assets$2.3B+0.8%

Cash flow

See full

Operating cash flow$13.5M-67.6%

CapEx$2.9M-23.5%

Free cash flow$10.6M-72.0%

Valuation

See full

Market cap$1.07B-34.0%

Enterprise value$1.89B-23.5%

P/E19.4×+5.8×

P/S0.8×-0.5×

Profitability

See full

Gross margin55.2%-1.0pp

Operating margin8.2%-5.6pp

Net margin4%-5.0pp

FCF margin9%-3.5pp

Returns & leverage

See full

Return on equity5.5%-7.5pp

Debt / equity0.8×-0.1×

Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CONMED's cash & equivalents?: CONMED (CNMD) reported cash & equivalents of $35.03M in Q1 2026.
How has CONMED's cash & equivalents changed year-over-year?: CONMED's cash & equivalents decreased by 1.3% year-over-year, from $35.49M to $35.03M.
What is the long-term trend for CONMED's cash & equivalents?: Over 5 years (2020 to 2025), CONMED's cash & equivalents has grown at a 8.3% compound annual growth rate (CAGR), from $27.36M to $40.82M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.